Ascletis Pharma Inc. (HKEX: 1672) announced that preclinical data for its ASC36_35 fixed-dose combination (FDC) drug candidate will be presented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE